{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:44Z","timestamp":1786119344825,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/bor.0b013e32832ca447","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T03:22:57Z","timestamp":1243221777000},"page":"374-379","source":"Crossref","is-referenced-by-count":31,"title":["New selective estrogen and androgen receptor modulators"],"prefix":"10.1097","volume":"21","author":[{"given":"Bart L","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/OGX.0b013e31816400d7","article-title":"Selective estrogen receptor modulators: an update on recent clinical findings","volume":"63","author":"Shelly","year":"2008","journal-title":"Obstetr Gynecol Surv"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djk062","article-title":"SERMs: meeting the promise of multifunctional medicines","volume":"99","author":"Jordan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/PPO.0b013e318161d13e","article-title":"Novel concepts in androgen receptor blockade","volume":"14","author":"Hsieh","year":"2008","journal-title":"Cancer J"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1124\/mi.7.1.3","article-title":"Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5\u03b1-reductase?","volume":"7","author":"Gao","year":"2007","journal-title":"Mol Interv"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/mend.11.6.0009","article-title":"Coactivator and corepressor regulation of the agonist\/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen","volume":"11","author":"Smith","year":"1997","journal-title":"Mol Endocrinol"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0092-8674(00)00188-4","article-title":"Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription","volume":"103","author":"Shang","year":"2000","journal-title":"Cell"},{"key":"R7-12-20210128","first-page":"659","article-title":"Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens","volume":"9","author":"McDonnell","year":"1995","journal-title":"Mol Endocrinol"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/42750","article-title":"A signature motif in transcriptional co-activators mediates binding to nuclear receptors","volume":"387","author":"Heery","year":"1997","journal-title":"Nature"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0039-128X(02)00112-5","article-title":"Receptor profiling and endocrine actions of tibolone","volume":"68","author":"de Gooyer","year":"2003","journal-title":"Steroids"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1073\/pnas.0808742106","article-title":"The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol","volume":"106","author":"Billon-Gal\u00e9s","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/humupd\/2.6.483","article-title":"Development, pharmacology, and clinical experience with clomiphene citrate","volume":"2","author":"Dickey","year":"1996","journal-title":"Hum Reproduct Update"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/BF02383389","article-title":"Raloxifene: a selective estrogen receptor modulator","volume":"12","author":"Sato","year":"1994","journal-title":"J Bone Miner Res"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/0008-5472.CAN-09-0029","article-title":"A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention","volume":"69","author":"Jordan","year":"2009","journal-title":"Cancer Res"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors ER\u03b1 and \u03b2","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1200\/JCO.2006.09.5992","article-title":"Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer","volume":"25","author":"Deshmane","year":"2007","journal-title":"J Clin Oncol"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"e010","DOI":"10.1621\/nrs.06010","article-title":"Selective androgen receptor modulators in preclinical and clinical development","volume":"6","author":"Narayanan","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1210\/endo.140.10.7039","article-title":"Androgen-induced regrowth in the castrated rat ventral prostate: role of 5\u03b1-reductase","volume":"140","author":"Wright","year":"1999","journal-title":"Endocrinology"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.nucmedbio.2006.05.009","article-title":"Synthesis and biological evaluation of a nonsteroidal bromine-76-labelled androgen receptor ligand 3-(76Br)bromo-hydroxyflutamide","volume":"33","author":"Parent","year":"2006","journal-title":"Nucl Med Biol"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M507464200","article-title":"Structural basis for accommodation of nonsteroidal ligands in the androgen receptor","volume":"280","author":"Bohl","year":"2005","journal-title":"J Biol Chem"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/en.2006-0843","article-title":"Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats","volume":"148","author":"Ostrowski","year":"2007","journal-title":"Endocrinology"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"R31-12-20210128","first-page":"424","article-title":"Structural basis for an unexpected mode of SERM-mediated ER antagonism.","volume":"412-","author":"Wu","year":"2005","journal-title":"Mol Cell"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chem Rev"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/156802606776173456","article-title":"Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential","volume":"6","author":"Cadilla","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s11095-006-9024-3","article-title":"Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands","volume":"23","author":"Gao","year":"2006","journal-title":"Pharm Res"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1210\/jcem.84.10.6122","article-title":"Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium","volume":"84","author":"Negro-Vilar","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1998.8209","article-title":"Discovery of nonsteroidal antiandrogens","volume":"244","author":"Dalton","year":"1998","journal-title":"Biochem Biophys Res Comm"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0960-894X(98)00107-3","article-title":"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino(3,2g) quinolinone","volume":"8","author":"Edwards","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/jpet.102.040840","article-title":"Pharmacodynamics of selective androgen receptor modulators","volume":"304","author":"Yin","year":"2003","journal-title":"J Pharmacol Exp Therapeut"},{"key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1248\/bpb.26.1563","article-title":"Bone anabolic effects of S-40503, a novel nonsteroidal androgen receptor modulator (SARM), in rat models of osteoporosis","volume":"26","author":"Hanada","year":"2003","journal-title":"Biol Pharmacol Bull"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/en.2006-0793","article-title":"An orally active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate","volume":"148","author":"Miner","year":"2007","journal-title":"Endocrinology"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32832ca447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:57:12Z","timestamp":1786039032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200907000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32832ca447","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}